Video Latest - ecancer

Taselisib with fulvestrant slows growth of advanced breast cancer

Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA

2 Jun 2018

Editor’s Choice for May 2018

Prof Gordon McVie - Founding Editor, ecancer

21 May 2018

Passage of treatments at the blood-brain barrier

Prof William Elmquist - University of Minnesota, Minneapolis, USA

11 May 2018

Incorporating biomarkers into clinical trial design

Dr Amar Gajjar - St. Jude Children's Research Hospital, Memphis, USA

11 May 2018

Dealing with peripheral neuropathic pain in multiple myeloma

Prof Wolfgang Grisold - Ludwig Boltzmann Gesellschaft, Vienna, Austria

2 May 2018

Managing infections in patients with multiple myeloma

Dr Joan Bladé - Hospital Clínic Barcelona, Barcelona, Spain

2 May 2018

Clinical management of plasma cell leukaemia

Dr Francesca Gay - University of Torino, Torino, Italy

2 May 2018

Editor's Choice for April 2018

Prof Gordon McVie - Founding Editor, ecancer

27 Apr 2018

Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer

Dr Arjun Balar - NYU Langone Medical Center, New York, USA

25 Apr 2018

Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099

Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical, New York, USA

25 Apr 2018

A variety of approaches to measure the efficacy of PARP inhibitors

Dr Elisabetta Leo - AstraZeneca, Cambridge, UK

25 Apr 2018

Development and clinical indications of PARP inhibitors

Dr Mark O'Connor - AstraZeneca, Cambridge, UK

25 Apr 2018

Video